Elevated LPA levels are associated with multiple disease pathologies including cancer, hydrocephalus, and fibrosis [3–6], implicating the therapeutic potential of modulating LPA pathways to reduce cognate receptor activity. The gene discussed is LPA; the disease is Hydrocephalus.